Hong Kongese chemical industry news

GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.

KMG debuts in the yuan market with Dim Sum bonds on AIX, diversifying funding and expanding its investor base. The issuance attracted high investor interest and positive analyst reviews.